Volkan Tekin

Dr. Volkan Tekin

Department of Physiology, Gulhane Faculty of Medicine, University of Health Sciences, Ankara, Turkey (Türkiye)
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2014 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
YDYavuz Dodurga
Yavuz Dodurga
GGGulsah Gundogdu
Gulsah Gundogdu
Volkan TekinVolkan Tekin
Volkan Tekin
TKTugba Koc
Tugba Koc
NSN. Lale Satiroglu-Tufan
N. Lale Satiroglu-Tufan
VKVural Kucukatay
Vural Kucukatay

16 July 2015 in Clinical Hemorheology and Microcirculation
Verified
Journal Article
Closed access
PDF file
EKEmine Kilic-Toprak
Emine Kilic-Toprak
AYAyşegül Yapıcı
Ayşegül Yapıcı
OKOzgen Kilic-Erkek
Ozgen Kilic-Erkek
YKYusuf Köklü
Yusuf Köklü
Volkan TekinVolkan Tekin
Volkan Tekin
MBMelek Bor-Kucukatay
Melek Bor-Kucukatay
In the present study, we investigated possible alterations in red blood cell (RBC) deformability, plasma and whole blood viscosities (WBV) and hematological parameters in response to Yo-Yo intermittent recovery test level 1 (Yo-YoIR1) which is curren

21 August 2026 in Healthcare
Verified
Journal Article
Open access
PDF file
Volkan TekinVolkan Tekin
Volkan Tekin
SDSümeyra Delibaş
Sümeyra Delibaş
EKEyüp Sina Keten
Eyüp Sina Keten
MŞMustafa Şahan
Mustafa Şahan
MKMehmet Koçer
Mehmet Koçer
SYSinan Yetkin
Sinan Yetkin
Background: Medical students are vulnerable to sleep disturbance and nocturnal eating behaviors that may jointly increase psychiatric and metabolic morbidity. Comprehensive sleep-eating evaluations in Turkish medical students remain limited. To determine the prevalence of poor sleep quality and night eating syndrome (NES) risk and to examine their cross-sectional associations with insomnia, anxiety, emotional eating, restless legs symptoms, chronotype, and lifestyle factors. Methods: This cross-sectional study, conducted from March to December 2023, included 265 medical students who completed validated instruments assessing sleep quality (Pittsburgh Sleep Quality Index [PSQI]), night eating syndrome (NES) risk (a score of ≥25 indicating high risk), insomnia severity, daytime sleepiness (Epworth Sleepiness Scale [ESS]), anxiety, emotional eating, Restless Legs Syndrome (RLS) symptoms, and chronotype. Group comparisons, Spearman’s correlation analyses, and multiple linear regression were conducted. Results: Poor sleep quality (PSQI > 5) affected 50.2% of participants, and high NES risk affected 14.7%. PSQI correlated with NEQ (r = 0.301; p < 0.001), insomnia severity (r = 0.538), anxiety, and emotional eating. Mean NEQ was higher in the poor-sleep group (18.67 ± 8.00 vs. 15.38 ± 6.36; p < 0.001; Cohen’s d = 0.455). Females had higher PSQI and ESS scores, anxiety, and emotional eating scores; high NES risk was numerically more frequent in males (18.6% vs. 11.8%; p = 0.175). RLS symptoms (score > 0) were present in 34.7% (mild 22.6%; moderate 7.9%; severe 4.2%). In the primary multivariable model (PSQI and sex), PSQI was the strongest independent correlate of NEQ (standardized β = 0.325; p < 0.001); sensitivity analyses showed stable PSQI estimates after additional covariate adjustment, whereas sex coefficients were non-significant and unstable across models. A secondary model excluding PSQI identified alcohol use as a significant lifestyle correlate (standardized β = 0.167; p = 0.014). R2 = 0.148 for the full covariate model and R2 = 0.108 for the primary model. Conclusions: Sleep disturbance and NES risk are prevalent and cross-sectionally associated in Turkish medical students. Poor sleep quality was the strongest independent correlate of night eating scores. Integrated campus screening targeting sleep, eating behavior, anxiety, and comorbid sleep symptoms may facilitate prevention and referral.

11 May 2021
Verified
Book
Open access
PDF file
GAGÜLAY AÇAR
GÜLAY AÇAR
GCGulsemin Cicek
Gulsemin Cicek
EÖEmine Utlu Özen
Emine Utlu Özen
RÇRuksan Çopuroğlu
Ruksan Çopuroğlu
BGBuket Gedik
Buket Gedik
MGMeltem Gümüş
Meltem Gümüş
Karaciğer Anatomisi Gülay Açar Karaciğer Histolojisi ve Embriyolojisi Gülsemin Çiçek Emine Utlu Özen Karaciğer Hastalıklarının Patolojisi Ruksan Çopuroğlu Buket Gedik Karaciğerin Benign Kitlelerinin Patolojisi Ganime Çoban Yeliz Arman Karakaya Karaciğer Prekürsör Lezyonlarının ve Malign Tümörlerinin Patolojisi Döndü Nergiz Hülya Tosun Yıldırım Karaciğerin Hücresel Hasarı ve Fibrozis Yeliz ARMAN KARAKAYA Şirin KÜÇÜK Harun KÜÇÜK Karaciğer Fizyolojisi Ve Hücresel Fonksiyonları Güven GÜVENDİ Saime ÖZBEK ŞEBİN Safra Oluşumu Ve Fizyolojisi Metin Yalaza Yavuz Çağır İntestinal Flora Ve Karaciğer Hastalıkları -1 Murat Deveci Hafize Kızılkaya İntestinal Flora Ve Karaciğer Hastalıkları - 2 Esma Eroğlu Arzu Tarakçı Karaciğer ve İmmünite Gökçe Kundakçı Gelir Berrin Yalınbaş Kaya Hepatosellüler Karsinomun Moleküler Mekanizmaları Levent Elmas Mücahit Seçme Hepatosit Transplantasyonu Ve Kök Hücre Gülsemin Çiçek Karaciğer Ve Sirkadiyen Ritim Volkan TEKİN Karaciğer Fonksiyon Testleri Ve Güncel Gelişmeler Türkan Güney Ali Karataş Sarılıkta Patofizyoloji Ve Klinik Değerlendirme Tuba Erürker Öztürk Gebelik ve Karaciğer Özlem Koşar Can Batuhan Başpınar Karacı̇ğer ve Beslenmeye Klı̇nı̇k ve Moleküler Açıdan Yaklaşım Hatice Hamarat Özge Alkan Tali Karaciğer Hastalıklarında Girişimsel Endoskopik Yöntemler Mehmet Alpua Karaciğer Hastalıklarında Görüntüleme Mustafa Devran Aybar Karaciğerin Benign ve Malign Hastalıklarında Görüntüleme Mahmut ÇORAPLI Kamil DOĞAN Karaciğer Tümörlerinde Girişimsel Yöntemlere Cerrahi Bakış Sait Tayfun Karaciğer Hastalıkları Ve Girişimsel Radyoloji Seda Nida Karaküçük Karaciğer Tümörleri Ve Girişimsel Radyoloji Muhammet ARSLAN Halil Serdar ASLAN Karaciğer Kitlelerinde Tanı Ve Semptomatoloji Yonca Yılmaz Ürün Ferhat Bacaksız Karaciğerin Benign Kitleleri Murat Pekgöz Sevil Özer Sarı Karaciğerin Malign Kitleleri Mustafa Gürkan Haytaoğlu Karaciğerin Malign Kitlelerinde Medikal Onkoloji Ve Tedavi Rejimleri Sabri Güncan Kronik Karaciğer Hastalıklarının Etiyolojisi ve Klinik Yaklaşım Barış Soydaş Viral Hepatitler İle İlgili Genel Bilgiler Sercan Kiremitçi Hepatit B Ve D Enfeksiyonlarına Yaklaşım ve Tedavi Berk Baş Ramazan Gözüküçük Hepatit C’ye Yaklaşım ve Tedavi Zuhal Yeşilbağ Murat Pekgöz Hepatit A Virüs Enfeksiyonu Esma Kepenek Kurt Mevlüt Kıyak Hepatit E Virüs Enfeksiyonu ve Klinik Yaklaşım Esma EROĞLU Mesut GÜMÜŞSOY Sistemik Viral Enfeksiyonlar ve Karaciğer Şaban İNCECİK Vedat KILIÇ Alkolik Hepatit Rahmi ASLAN Yaren DİRİK Non-Alkolik Yağlı Karaciğer Hastalığı Tanı ve Tedavi Yaklaşımı Yakup ÜLGER Derya ARI Otoimmün Hepatit Tanı Ve Tedavisi Yavuz ÇAĞIR Primer Biliyer Kolanjit, Sekonder Biliyer Siroz, Primer Sklerozan Kolanjit, Sekonder Sklerozan Kolanjit Çağdaş Erdoğan Mehmet Köroğlu Budd-Chiari Sendromu Ve Venookluziv Hastalıkta Tanı Ve Tedavi Fatih EREN Berrin YALINBAŞ KAYA İlaç İlişkili Karaciğer Yetmezliği: Etkenler, Tanı Ve Tedavi Filiz ARAZ Akut Karaciğer Yetmezliği Murat İSPİROĞLU Mesut AYDIN Kronik Karaciğer Hastalıklarında Akut Alevlenmeler ve Yaklaşım Mustafa AKAR Çınar YILDIRIM Siroz Tedavisinde Kullanılan Başlıca İlaçlar Elif Tuğba TUNCEL Karaciğer Sirozu Ve Dekompansasyon Bilal TOKA Salih TOKMAK Karaciğer Sirozu Ve Tüm Yönleriyle Laboratuvar Değerlendirme Berat EBİK Hüseyin KAÇMAZ Portal Hipertansiyon Kübra AKAN Portal Hipertansiyona Cerrahi Yaklaşım Ufuk ARSLAN Portal Ven ve Splenik Ven Trombozuna Klinik ve Cerrahi Yaklaşım Fatih KIVRAKOĞLU Murat GÜNER M.Fevzi CELAYİR Karaciğer Hastalıklarında Anamnez Ve Fizik Muayene Mehmet KÖROĞLU Karacığer Hastalıkları Ve Nörolojık Bulgular Güven ARSLAN Hepatorenal Sendrom Murat DEVECİ Vedat GENÇER Hepatopulmoner Sendrom, Portopulmoner Hipertansiyon Çağdaş Erdoğan Mehmet Fatih Elverişli Karaciğer Hastalıkları Ve Hematopoietik Sistem, Hemostaz Funda Pepedil Tanrıkulu Filiz Araz Karaciğerin Paraziter Hastalıkları Ve Medikal Tedavi Safiye Koçulu Demir Karaciğerin Paraziter Hastalıklarında Cerrahi Tedavi Özhan Albayrak Ali Sürmelioğlu Karaciğerin Bakteriyel ve Mantar Enfeksiyonları ve Apselerine Medikal Yaklaşım Suzan Şahin Nazım Ekin Karaciğerin Bakteriyel Ve Mantar Enfeksiyonlarına Ve Apselerine Cerrahi Yaklaşım Sami Benli Dursun Burak Özdemir Karaciğer Nakli Öncesi Hasta Ve Donör Hazırlığı Şencan Acar Karaciğer Naklinde Endikasyon ve Kontrendikasyonlar Muhammed Raşid Aykota Şencan Acar Karaciğer Nakli...

22 May 2026 in Bratislava Medical Journal
Verified
Journal Article
Open access
SSSerpil Suvay
Serpil Suvay
ZCZehra Cicek
Zehra Cicek
Volkan TekinVolkan Tekin
Volkan Tekin
GKGokhan Burcin Kubat
Gokhan Burcin Kubat
BBBarıs Baykal
Barıs Baykal
MOMehmet Ozler
Mehmet Ozler
Objective: Cancer cells derive the majority of their energy necessary for rapid proliferation and growth through glycolysis, irrespective of oxygen availability and mitochondrial functionality. Mitochondrial transfer has been explored as an innovative therapeutic approach for various diseases; however, there are divergent perspectives on whether mitochondrial dysfunction—frequently observed in cancer cells—is a cause or a consequence of tumor progression. 3-BP inhibits hexokinase, thereby blocking the entry step of glycolysis. This study aims to investigate the effects of 3-Bromopyruvic acid (3-BP), a hexokinase inhibitor, in conjunction with mitochondrial transfer on DU-145 prostate cancer cells. Materials and methods: In this study, human bone marrow-derived mesenchymal stem cells (HMSCs) were utilized as donors for isolated mitochondria intended for mitochondrial transfer. ATP levels of the isolated mitochondria were quantified. The mitochondria were labeled with Mitotracker Red CMXRos or MitoSpy Green, and fluorescence microscopy was used to assess co-localization of donor-derived mitochondrial signal with recipient cells, interpreted as evidence compatible with cellular association/uptake rather than proof of stable integration. Mitochondrial transfer was conducted by co-incubating the mitochondria with DU-145 cells with the addition of various doses of 3-BP for 24 and 48 h. The sensitivity of the cells to 3-BP and cell proliferation post-mitochondrial transfer were evaluated using the MTT assay (3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide). Apoptosis and in situ cell death were assessed employing the TUNEL method. Caspase-3 levels were measured via ELISA, while mTOR and HIF1α protein expressions were determined through western blot analysis. Results: The antiproliferative efficacy of 3-BP alone and in conjunction with mitochondrial transfer was evaluated in DU-145 cells. Mitochondria isolated from HMSCs exhibited viability and functionality, maintained adequate ATP levels, and showed donor-derived signal detectable inside recipient cells alongside recipient mitochondrial staining in DU-145 cells. While 3-BP application significantly inhibited the proliferation of DU-145 cells, mitochondrial transfer alone did not show a significant antiproliferative effect. However, the sequential application of both treatments effectively suppressed cell growth. Sequential treatment resulted in a reduction of overall mTOR and HIF-1α protein levels as determined by Western blot analysis under the specified experimental conditions. These measurements denote relative expression levels; however, they do not, in isolation, confirm the activity of the mTOR pathway. Caspase-3 activity and TUNEL positivity remained unaltered across different groups, which aligns with the assay-specific detection of distinct apoptotic features observed at a single time point. Conclusion: This study, in addition to being the first in vitro investigation of sequential mitochondrial transfer with 3-BP administration in prostate cancer cells, demonstrated that inhibiting glycolysis and mitochondrial transfer may serve as significant, alternative adjunctive approaches in cancer therapy.

18 September 2026 in Experimental and Molecular Pathology
Verified
Journal Article
Open access
Volkan TekinVolkan Tekin
Volkan Tekin
ZÇZehra Çiçek
Zehra Çiçek
GKGizem Esra Koç
Gizem Esra Koç
MÖMehmet Özler
Mehmet Özler
Cisplatin is an effective chemotherapeutic agent with dose-limiting toxicity in non-target tissues. Hyperbaric oxygen therapy (HBOT) and mitochondrial transplantation (MitoTr) have been explored as supportive strategies in preclinical models. We examined whether HBOT and/or MitoTr modulate cisplatin-associated reductions in MTT metabolic activity and oxidative balance in healthy human mesenchymal stem cells (hMSCs) under incubator versus hyperbaric conditions. Bone marrow-derived hMSCs were seeded at 5 × 103 cells/well and exposed to cisplatin at an experimentally determined MTT-based LD50 (148 μM; 150 μM used). A delayed adjunctive intervention protocol was applied after LD50-level exposure: cisplatin or vehicle for 24 h, followed by 4 h MitoTr co-incubation (10× or 100× cell-number-scaled dose), then three HBOT sessions (90 min, 2.1 ATA) or matched incubator control. Endpoints were MTT absorbance (NAD(P)H-dependent oxidoreductase activity), total antioxidant status, total oxidant status, and oxidative stress index, analyzed by two-way ANOVA with Tukey post hoc. At 150 μM cisplatin, MTT absorbance was markedly reduced in all cisplatin-containing groups under both conditions (all p < 0.001 vs controls), and neither HBOT nor MitoTr restored MTT signal to control levels. Among cisplatin-free groups, M10 under HBOT exceeded control HB MTT absorbance (p = 0.009), whereas M10 under incubator conditions did not differ from control. HBOT reduced baseline MTT absorbance in cisplatin-free groups relative to matched incubator controls (p < 0.001). MitoTr lowered oxidant status under incubator conditions; HBOT improved redox indices in mitochondria-free groups. Under the LD50-level conditions tested, neither HBOT nor MitoTr restored NAD(P)H-dependent oxidoreductase (MTT) activity in hMSCs. Under non-toxic conditions, both modalities produced context-dependent redox changes. Whether lower, clinically relevant cisplatin exposures would yield partial protection remains an open question.